FN2 Earnings Intelligence
Elevance Health Inc. financials
Elevance Health Inc. (ELV) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $4,880 | $7,387 | $6,526 | $8,288 | $9,491 | - | - |
| + Debt | $21,432 | $22,614 | $23,471 | $29,583 | $30,947 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $138,639 | $156,595 | $171,340 | $177,011 | $199,125 | $196,962.1 | $201,374.9 |
| % Growth | 13.8% | 13.0% | 9.4% | 3.3% | 12.5% | -1.1% | 2.2% |
| Gross Profit | $127,744 | $143,560 | $154,047 | $157,261 | $177,947 | - | - |
| % Margin | 92.1% | 91.7% | 89.9% | 88.8% | 89.4% | - | - |
| EBITDA | $7,625 | $8,575 | $8,606 | $7,967 | $7,293 | - | - |
| % Margin | 5.5% | 5.5% | 5.0% | 4.5% | 3.7% | - | - |
| Net Income | $6,104 | $6,025 | $5,987 | $5,980 | $5,662 | - | - |
| % Margin | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% | - | - |
| Diluted EPS | $24.73 | $24.81 | $25.22 | $25.68 | $25.21 | $27.13 | $29.58 |
| % Growth | 37.5% | 0.3% | 1.7% | 1.8% | -1.8% | 7.6% | 9.0% |
| Operating Cash Flow | $8,364 | $8,399 | $8,061 | $5,808 | $4,290 | - | - |
| CapEx | $1,087 | $1,152 | $1,296 | $1,256 | $1,116 | - | - |
| Free Cash Flow | $7,277 | $7,247 | $6,765 | $4,552 | $3,174 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $138,639 | $156,595 | $171,340 | $177,011 | $199,125 | $196,962.1 | $201,374.9 |
| Gross Profit | $127,744 | $143,560 | $154,047 | $157,261 | $177,947 | - | - |
| EBITDA | $7,625 | $8,575 | $8,606 | $7,967 | $7,293 | - | - |
| Net Income | $6,104 | $6,025 | $5,987 | $5,980 | $5,662 | - | - |
| Diluted EPS | $24.73 | $24.81 | $25.22 | $25.68 | $25.21 | $27.13 | $29.58 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4,880 | $7,387 | $6,526 | $8,288 | $9,491 |
| Short-term Debt | $275 | $265 | $225 | $365 | $150 |
| Long-term Debt | $21,157 | $22,349 | $23,246 | $29,218 | $30,797 |
| Total Debt | $21,432 | $22,614 | $23,471 | $29,583 | $30,947 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $8,364 | $8,399 | $8,061 | $5,808 | $4,290 |
| Capital Expenditure | $1,087 | $1,152 | $1,296 | $1,256 | $1,116 |
| Free Cash Flow | $7,277 | $7,247 | $6,765 | $4,552 | $3,174 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 13.8% | 13.0% | 9.4% | 3.3% | 12.5% |
| Gross Margin | 92.1% | 91.7% | 89.9% | 88.8% | 89.4% |
| EBITDA Margin | 5.5% | 5.5% | 5.0% | 4.5% | 3.7% |
| Net Margin | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% |
| FCF Margin | 5.2% | 4.6% | 3.9% | 2.6% | 1.6% |
| Diluted EPS Growth | 37.5% | 0.3% | 1.7% | 1.8% | -1.8% |